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Background: Postpartum Depression affects a considerable number of women worldwide. This condition
inﬂicts severe consequences to mother and child health. Thus far, available treatments have low response
and high relapse rates. We designed this trial to evaluate a safe and more efﬁcacious innovative therapy.
Aims: To report a feasible and ethical study design to assess the safety and efﬁcacy of a high frequency
repetitive Transcranial Magnetic Stimulation 10 Hz (rTMS) compared to sham rTMS in women with
moderate to severe Post-Partum Depression using standard treatment (sertraline).
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To conduct an ancillary, exploratory, randomized, active controlled, double blind study with a hypothesis
to assess the safety and efﬁcacy of 10 Hz rTMS compared to sertraline.
Methods: A multicenter, parallel arm, randomized, placebo-controlled, double-blind design to assess
safety and efﬁcacy of 10 Hz rTMS compared to sham.
An ancillary study will be conducted with parallel arm, randomized, active controlled and double dummy
design to assess safety and efﬁcacy of 10 Hz rTMS compared to sertraline.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
As of 2012, the Diagnostic and Statistical Manual of Mental
Disorders-5 redeﬁned postpartum depression (PPD) as a subset of
Major Depressive Disorder (MDD) persistent up to 4 weeks after
delivery with a peripartum onset [1]. AlthoughMDD and PPD share
many clinical similarities, a meta-analysis of 11 randomized clinical
trials showed differences between the diseases on neuroimaging,
gonadal steroidal hormone involvement, and response to treat-
ments [2].
Postpartum Depression has a prevalence of 14% in the general
population of pregnant women [3]. It is responsible for maternal
suicide and infanticide in the most severe cases [4]. Studies have
shown that PPD impairs maternal-newborn bond producing a
greater risk of child abuse and negligence; resulting in irreversible
cognitive and social deﬁcits later in child life [3,5]. Postpartum
depression is the number one cause of maternal morbidity after
childbirth [6].
The ﬁrst-line therapy for moderate to severe PPD is of Selective
Serotonin Reuptake Inhibitor (SSRI) such as sertraline [3,7].
Although it is considered relatively safe for breastfeeding, mothers
still have a concern regarding newborn consumption of drug me-
tabolites in the breast milk compromising treatment adherence
[8,9]. Additionally, the efﬁcacy of SSRI has come into question with
low response rates and high relapse rates. High latency to response
of these SSRI also plays an important role for this population and
reconciling the mother-to-child bond. Hence there is a need to test
new therapies for this speciﬁc population.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a
noninvasive brain stimulation technique that has been FDA
approved in the treatment of refractory MDD [10]. rTMS functions
by eliciting focal magnetic waves to the brain. It induces neuro-
plasticity by promoting synaptogenesis in targeted cortical areas
[11]. Low frequency rTMS stimulates inhibitory GABA neurons
while high frequency stimulates the excitatory neurons. This
treatment modality combined with standard therapy has demon-
strated a faster response in MDD compared to standard therapy
alone [12]. This results in a reduced exposure to SSRI adverse
effects.
Only two pilot studies thus far have evaluated the effects of
rTMS in PPD patients. Both trials showed safety and positive results
of combined therapy of rTMS and SSRI [13,14]. This warrants further
investigation of this treatment modality as a viable option in
women with PPD to modulate the effect of standard therapy by
increasing its efﬁcacy. It has potential to reduce time to response
and adverse effect proﬁle of treatment.
In this trial, we aim to investigate the safety and efﬁcacy of high
frequency rTMS (10 Hz) compared to sham rTMS in women with
moderate to severe PPD using standard therapy (sertraline). This
would pave the way towards ﬁnding a safe and efﬁcacious
evidence-based therapy for postpartum depression and with a
better safety proﬁle than standard therapy alone. By adding a third
arm, we also aim to conduct an ancillary, exploratory, double
dummy study [23] to assess the safety and efﬁcacy of rTMS
compared to Sertraline. To our knowledge, this direct comparison
has never been evaluated in patients with postpartum depression
and would provide a basis for future trials.
2. Methods
2.1. Trial design
A multicenter, parallel arm, randomized, placebo-controlled,
double-blind study design to assess safety and efﬁcacy of 10 Hz
rTMS compared to sham rTMS in postpartum depressed patients
using standard treatment (sertraline). A third arm with patients
using 10 Hz rTMS þ placebo is needed to address the ancillary
hypothesis. The ancillary study will be conducted as a parallel arm,
randomized, active controlled and double dummy design to assess
safety and efﬁcacy of 10 Hz rTMS compared to sertraline. Subjects
will be randomly allocated to either arm 1, 2 or 3 in a 2:2:1 ratio by
random blocks of 3 or 6 subjects. Stratiﬁcation will be done to
control for study center.
Treatment will start after delivery once our screening process
conﬁrms PPD. Active and sham rTMS will be administered for a 6
weeks Treatment Phase and a 6 weeks Maintenance Phase
following pivotal trial and FDA guidelines for TMS and Major
Depression [10]. 50 mg Sertraline and placebo will be given for 12
weeks duration with possible increase of an additional 50 mg.
2.2. Participants
Women over 18 years of age, with moderate to severe PPD
(based on HAMD-17 scale score >18) will be included. We will
exclude patients based on three broad categories of contraindica-
tions for rTMS, contraindications for SSRI therapy (for safety), and
based on confounders that may affect our outcomes. Table 1 sum-
marizes the eligibility criteria.
2.2.1. Study setting
In order to achieve sufﬁcient generalizability of the results, and
to ease the burden of recruitment, this trial will be a multicenter
trial. To our knowledge, this is the ﬁrst multi-center trial testing the
safety and efﬁcacy of rTMS in PPD patients. The trial will be con-
ducted at four study sites in USA, Brazil, Portugal and Turkey.
2.2.2. Study site eligibility criteria
1. All necessary equipment and infrastructure available, including
qualiﬁed, trained and licensed staff, rooms, laboratory with
necessary equipment for rTMS.
2. Proven ability to reach recruitment milestones by access to our
target patient population.
3. Approval from the Ethical Committee of each site
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2.3. Intervention
In our trial, active rTMS (Arms 1 and 3) or sham rTMS (Arm 2)
will be applied to the Left Dorsolateral Prefrontal Cortex (LDLPFC)
of all patients. The left DLPFC is a common target for rTMS and has
been used in several major trials that proved efﬁcacy in MDD
[13e15]. Wewill localize the LDLPFC by using the “5 cm rule” [16], a
standard procedure to accurately ﬁnd the LDLPFC for the applica-
tion of rTMS.
The rTMS protocol recommended by the FDA [17] calls for a
treatment phase of 30 sessions over 6 weeks followed by a tapered
6-week maintenance phase of 7 sessions. The schedule of sessions
can be found in Table 2. Patients will undergo a total of 37 sessions
of 10 Hz rTMS stimulation to their LDLPFC as follows: 75 trains
(3000 pulses) per day, each train lasted 4 s and 26 s off between
trains, for a total of 37.5 min. Sham rTMS in Arm 2 will follow an
identical schedule and will mimic the active intervention. The
equipment to be use is the MagVenture MagPro R380. Due to its
manufacturing features, it is possible to apply sham and active
rTMS, maintaining our double blind study design.
2.4. SSRI rationale & dosing
First line treatment of moderate to severe PPD is either Sertra-
line or Paroxetine. Although both drugs have shown no incidence of
infant abnormalities [18], we referred to several systematic reviews
and trials comparing SSRI metabolite content in breast milk and in
infant serum and concluded that Sertraline had a slightly safer
proﬁle than Paroxetine [19]. Additionally, Psychiatric guidelines
recommend the use of sertraline rather than paroxetine for PPD [8].
Thus, patients in all arms, will be given the initial dose of 50 mg
Sertraline (Arms 1 & 2), or placebo (Arm 3) orally, once daily. The
drug will be given at the same time as the rTMS procedure and
patients will be given doses to take home during weekend. The
dose of sertraline or placebo may be increased by 50 mg per week
up to a total of 200 mg, if no improvement within two weeks as
deemed by the recommendations of the Data Safety Monitoring
Committee.
2.5. Outcome
Our primary endpoint is the absolute change in the 17 item
Hamilton Depression Scale Score between patients in Arm 1 and
Arm 2. For comparability with previous studies, this validated scale
will be our primary outcome to assess efﬁcacy of 10 Hz rTMS over
sham rTMS.
Secondary endpoints include adverse event reporting, Edin-
burgh Post Natal Depression Scale (EPDS) changes, EEG changes,
Cortical Silence Period (cSP), 36-Item Short Form Survey (SF-36)
quality of life scale, and neurocognitive battery tests (Victoria
Stroop, Wisconsin card sorting test, controlled oral word associa-
tion test). Table 3 summarizes the data collection schedule for all
the outcomes.
2.6. Randomization
Upon meeting eligibility criteria and signing informed consent,
patients will be randomized in a 2:2:1 (Arm 1: Arm 2: Arm 3) ratio
in random blocks of 3 or 6 participants per block. Randomization
will be stratiﬁed by study center. A computer-generated randomi-
zation sequence will be issued and an outsider clinician will assign
allocation by Interactive Voice Response System.
2.7. Blinding
Investigator, stimulator, assessors, patients, and study staff
during the trial will be blinded. Blinded assessors will collect data
such as HAM-D17 scale score, SF-36, EPDS, adverse event report.
In order to maintain blinding, sertraline will have a matched
placebo pill (appearance, texture & taste). Both drugs will be
administered in identical containers according to the treatment-
code generated by computer randomization. An open label study
pharmacist will dispense it.
The trained rTMS operator will be blinded. They will be
responsible for applying rTMS treatment and to collect EEG and cSP
data after each intervention. To maintain the blinding in this role,
we will use the Mag Venture TMS device. This device has a two-
sided coil; one side is for sham TMS and the other for the active
treatment. Both procedures will appear identical. Upon entering
the patient ID into the device, it will guide the stimulator to the
unmarked appropriate positioning of the coil (sham or active) ac-
cording to the pre-determined, saved randomization sequence.
This feature ensures that the responsible for the brain stimulation
remains blinded.
Blinding will be assessed at the end of the trial by a question-
naire completed by stimulators, assessors, investigators and pa-
tients. In case of patients dropping out of the study, those will be
contacted and encouraged to complete the questionnaire.
2.8. Unblinding
In cases of Severe Adverse Effects (SAE), the Data Safety Moni-
toring Committee will provide guidance on the need for unblind-
ing. The IVRS system accounts for a code breaking option that only
the open label pharmacist has access to. In case of unblinding,
investigator will keep records of the date, time, and reasons for
unblinding and patient exclusion from the trial. Unblinding is
authorized in cases of severe emergency that require information
about treatment received by the patient in order to provide
appropriate medical care. Unblinding information will only be
Table 1
Eligibility criteria.
Inclusion
Females who have completed delivery
>18 years old
Conﬁrmed PPD diagnosis by DSM-5 criteria
Moderate to Severe Depression by score of >18 score on HAM-D17 scale
Exclusion
rtms contraindications
Previous Stroke, Seizure or CNS Disease
Previous or current drug or alcohol abuse
Ferromagnetic metallic implants
SSRI therapy contraindications
Bipolar Depression or previously diagnosed mental health disorder
Allergy to components of the medication
History of Liver or kidney Disease
Other exclusions
Previous 6 month treatment with SSRI or rTMS prior to randomization
Suicidal ideation and History of suicidal attempt
Puerperal blues
Secondary causes of Depression (e.g. Hypothyroidism, Sheehan Syndrome etc.)
Table 2
Treatment phases.
Time Frequency of rTMS administration
Treatment phase Week 1e6 5 times per week
Maintenance phase Week 7 3 times per week
Week 8 2 times per week
Week 9 1 time per week
Week 11 1 time per week
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revealed to study staff that is deemed necessary for patient safety.
2.8.1. Discontinuation/stoppage criteria
 Discontinuation from the study may occur under the following
circumstances:
 Patient withdraws consent from the trial.
 Sudden or severe changes in the patient's psychiatric,
neurological function or general medical condition related to
the intervention(s) administered in the trial.
 Receiving external medical attention that are contraindication
to the intervention administered in the trial.
 Non-compliance.
2.9. Sample size
Sample sizewas calculated to have 80% power to detect an effect
size of 0.67, with a signiﬁcance alpha level of 0.05 for the primary
hypothesis. A drop out rate of 10% was considered. The effect size
was estimated based on historical data from previous trials with
major depression, SSRI and rTMS [20]. We used this data to base our
calculations of the effect size due to the new classiﬁcation of DSM-V
that considers PPD an onset of major depression. All the calcula-
tions were performed on Stata providing a ﬁnal sample size of 100
subjects.
2.10. Statistical analysis
Baseline characteristics will be assessed by ANOVA. The primary
outcomewill be assessed by t-test. Secondary analysis to control for
covariates such as sertraline dose, age, and estrogen level will be
performed by ANCOVA with an Intention to Treat (ITT) analysis.
Kaplan-Meier and Cox-PH models with censoring for missing data
will be used to evaluate time to remission of PPD. For the survival
analysis, time-to-remission will be deﬁned as the time to achieve a
change of 50% on baseline HAM-D17 scale score through 6 and 12
weeks. Descriptive statistics will be used for safety analysis and EEG
changes. Table 4 summarizes the main tests for primary and sec-
ondary hypotheses.
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3. Discussion
3.1. Rationale for the trial design
For this study, several trial designs were considered to evaluate
safety and efﬁcacy of rTMS on PPD based on existing knowledge
and ethical concerns with the study population. We considered
several study designs such as a non-inferiority design to our two
arm and double blind trial compared to sertraline, a superiority
trial and our current design with an exploratory question.
In order to prove non-inferiority of rTMS compared to sertraline,
two primary considerations were taken into account: assay sensi-
tivity and inferiority margin calculation. Assay sensitivity poses a
challenge due to the moderate effect size of SSRI over placebo. A
meta-analysis of RCTs showed a 1.01 odds ratio at the lower margin
of the conﬁdence interval. This means that in themost conservative
estimation, there is no signiﬁcant difference between SSRI and
placebo [21]. This makes the choice of an appropriate inferiority
margin unfeasible to detect the expected effect size. Therefore,
although it would be an interesting study design, there is not
enough data supporting the notion that rTMS non inferiority over
SSRI represents a true effect over placebo rather than equivalent
ineffectiveness over placebo.
Our second option was a two-arm double-dummy superiority
design to test rTMS over sertraline. While this design has the
advantage of a direct comparison of the two treatments as mono-
therapies, no direct comparison between both interventions has
been done previously in this population. Hence, there is not enough
evidence to support this design, and it is not prudent to conduct a
larger late phase II trial without a precedent pilot trial.
Therefore, we designed a study that would provide evidence
regarding the efﬁcacy of rTMS compared to sham rTMS in
postpartum depressed women under standard treatment (sertra-
line). This design allows the evaluation of the combination therapy
(rTMS and SSRI) over standard mono-therapy in the PPD popula-
tion through the primary question - a phenomenonwith numerous
supporting literature [13e15]. Meanwhile, it admits an ancillary
question involving an exploratory evaluation of rTMS over sertra-
line mono-therapy. Regardless of positive or negative results, this
will pave the way for future head-to-head comparison trials.
3.2. Recruitment strategy
We target to keep the inclusion criteria as general as possible in
order to encompass all women over 18 years old who have mod-
erate to severe PPD. As a late phase II trial, this provides the
generalizability required for a pivotal device trial. We also followed
the guidance of the previous two pilot PPD trials [13,14].
We expect low drop-out rates based on acceptability of the
treatment [11] and previous pilot studies that demonstrated high
adherence rates for this population receiving rTMS combined with
SSRI [13,14]. Despite this, we will use several retention strategies
such as, providing regular communication with patients, compen-
sating for transportation, involving family members as much as
possible, and offering childcare services while the patient un-
dergoes treatment. Furthermore, to increase compliance, in-
vestigators will administer monitored doses of SSRI during study
visits for rTMS treatment. Data about safety of SSRI use, during
breastfeeding, will be shared with the patient. On days with no
rTMS treatment, patients will be given doses to take home with an
electronic diary to continuously monitor compliance.
Due to the time commitment required by patients in this trial,
and the time sensitivity to enroll the patient post-delivery, the
perceived challenge for this trial is not adherence but recruitment.
To address recruitment obstacles, we have a multicenter design to
reduce the recruitment burden at any particular site. In addition,
we will begin with a broad recruitment strategy early in the
pregnancy by public awareness campaigns that will aim to inform
expecting mothers of the prevalence of PPD, and the risks involved.
This strategy attempts to engage all expecting mothers who feel
they may be prone to mood disorders. We will also rely on referrals
by psychiatrists and obstetricians in order to have a wide selection
of potential participants in the targeted 4 week post-delivery
window period. Additionally, we will reach out to pediatricians to
give information about our trials to mothers of newborns receiving
their early childhood immunizations. All patients will be screened
for eligibility by our study team.
Our randomization strategy supports our recruitment targets.
We determined it would be favorable to randomize in a 2:2:1 ratio
as to have a favorable chance of enrolment into our primary arms of
the trial, only requiring a total of 72 completers (36 per arm) to
reach sufﬁcient power to detect the appropriate effect size.
Table 4
Study hypothesis, design, endpoint and statistical analysis.
Treatment ARM1 Treatment ARM 2 Endpoints Statistical analysis
Primary hypothesis - 6-week Treatment phase: 10 Hz
rTMS þ50 mg Sertraline once daily
- 6-week Maintenance phase: 10 Hz
rTMS þ Sertraline
- 6-week Treatment phase: Sham
rTMS protocol þ50 mg Setraline
- 6-week Maintenance phase: Sham rTMS
protocol þ50 mg Sertraline
Primary:
Reduction of 50% baseline
HAM-D17 scale score
Unpaired t-test based on
Central Limit Theorem
Treatment ARM 2 Treatment ARM 3 Endpoints Statistical analysis
Ancillary
hypothesis
- 6-week Treatment phase: Sham
rTMS protocol þ50 mg Setraline
- 6-week Maintenance phase:
Sham rTMS protocol þ50 mg Sertraline
- 6-week treatment phase: 10 Hz rTMS
protocol þ Placebo
- 6-week maintenance phase: 10 Hz
rTMS þ placebo
Secondary:
Reduction of 50% baseline
HAM-D17
scale score after 6 weeks
and 12 weeks time points
Unpaired t-test based on
Central Limit Theorem
Table 3
Time line for endpoints measurements.
Week
Outcome 0 1 2 3 4 5 6 7 8 9 10 11 12
SF-36 X X X
EPDS X X X
HAMD-17 X X X X X X X X X X X X
EEG X X X
cSP X X X X X X X X X X X X
Estrogen levels X X X X X
Safety lab tests X X X X X
SF-36: 36-Item Short Form Survey (SF-36).
EPDS: Edinburgh Post Natal Depression Scale.
HAMD-17: 17-item Hamilton Scale.
EEG: Electroencephalogram.
cSP: Cortical Silence Period.
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3.3. Ethical considerations
In dealing with a vulnerable population such as pregnant
women with a moderate to severe psychiatric condition, sound
ethical rationale must be incorporated into our study design.
Firstly, safety of rTMS procedure has been repeatedly demon-
strated in the general population and speciﬁcally in PPD patients in
pilot studies [13,14]. Secondly, since the effects of rTMS on pregnant
women have not been established to date, we will only initiate
treatment post-delivery. Thirdly, our randomization ratio allows for
80% of patients to receive standard therapy with active or sham
rTMS treatment. Only 20% of our patients will receive rTMS alone.
Although rTMSmonotherapy has a proven efﬁcacy in MDD [22], we
will employ a Data Safety Monitoring Committee to oversee all the
trial data in a blinded fashion on an ongoing basis. Patients with
worsening symptoms, or serious adverse events, will be evaluated
by the DSMC and guidance will be given in regards to SSRI dose
adjustment, unblinding, reverting to standard therapy or
discontinuation.
3.4. Limitations
In designing this trial, we perceive limitations that need to be
addressed. Blinding in medical device trials is a well-known chal-
lenge. In addition, our ancillary study may simply serve as a pilot
arm and results should be interpreted as such.
The MagVenture TMS device provides the added feature of an
unmarked single, two-sided coil for both sham and active treat-
ments allowing for a blinded operator. However; there are inevi-
table telltale signs of active and sham treatments by an experienced
stimulator. For instance, muscle twitches intensity during calibra-
tion by motor threshold and the stimulation itself. For this reason,
we will add an additional layer of protection against unblinding by
ensuring our blinded stimulator is unrelated to any other trial ac-
tivities, data analysis, and have limited contact with researchers. By
the same mechanism, patients with previous experience with
active rTMS may be unblinded by the differences between sham
and active treatments sensation. Therefore, these patients will be
excluded from the trial.
3.5. Strengths
We ﬁnd that this trial design allows for an ethical alternative to
evaluate a particularly vulnerable population that is difﬁcult to
study. This trial has the beneﬁt of evaluating rTMS as a combination
therapy as well as an exploratory monotherapy as a basis for future
trials. The ancillary exploration ﬁlls a gap in the literature that has
not been previously explored in this population. Furthermore, our
robust design, tests two parallel hypotheses using easily inter-
pretable statistical tests. Because of the strong evidence of TMS in
depressive disorders and FDA approval for this indication, we have
strongly validated outcomes to evaluate its efﬁcacy and a well-
established rationale for our hypothesis, making it likely to show
positive results.
4. Conclusion
We designed a study protocol scientiﬁcally feasible, ethical for
the investigation of an innovative treatment for PPD. In addition,
this subject is relevant for the scientiﬁc community, and has an
impact on women's health care and on public health.
Funding
This research did not receive any speciﬁc grant from funding
agencies in the public, commercial, or not-for-proﬁt sectors.
Acknowledgements
We thank the guidance by Dr Felipe Fregni, Laboratory of Neu-
modulation - Harward Medical School; and the entire team of
Principles and Practices of Clinical Research course of 2015.
References
[1] K. Stone, What the new DSM-V says about postpartum depression & psy-
chosis, Postpartum Prog. 1 (2013) 186e187. http://www.postpartumprogress.
com/what-the-new-dsm-v-says-about-postpartum-depression-psychosis.
[2] Fiorelli, Marco, et al., Magnetic resonance imaging studies of postpartum
depression: an overview, Behav. Neurol. (2015) 1e7. http://www.hindawi.
com/journals/bn/2015/913843/.
[3] D.R. Kim, C.N. Epperson, A.R. Weiss, K.L. Wisner, Pharmacotherapy of post-
partum depression: an update, Expert Opin. Pharmacother. 15 (9) (2014)
1223e1234, http://dx.doi.org/10.1517/14656566.2014.911842.
[4] A.A. Lembke, Psychosocial approach to postpartum depression, Psychiatr.
Times 20 (26) (June 2002).
[5] National Institute for Healthcare Management e NIHM. Identifying and
Treating Maternal Depression: Strategies & Considerations for Health Plans,
June 2010.
[6] Cindy-Lee Dennis, Peer support for postpartum depression: volunteers' per-
ceptions, recruitment strategies and training from a randomized controlled
trial, Health Promote Int. 28 (2) (June 2013) 187e196.
[7] Peter Roy-Byrne, Unipolar Major Depression in Pregnant Women: Treatment.
Uptodate.Com. N.P, 2016. Web. 13 Sep. 2015.
[8] Amstrong Carrie, ACOG guidelines on psychiatric medication use during
pregnancy and lactation, Am. Fam. Physician 78 (6) (2008 Sep 15) 772e778.
[9] T. Lanza, K. Wisner, Antidepressant medication use during breastfeeding, Clin.
Obstetrics Gynecol. 52 (3) (2009) 483e497. http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2902256/.
[10] J.C. Horvath, J. Mathews, M.A. Demitrack, A. Pascual-Leone, The NeuroStar
TMS device: conducting the FDA approved protocol for treatment of
depression, J. Vis. Exp. (2010), http://dx.doi.org/10.3791/2345. http://www.
jove.com/details.php?id¼2345. e2345, 1e3.
[11] B. Liu, Y. Zhang, L. Zhang, L. Li, Repetitive transcranial magnetic stimulation as
an augmentative strategy for treatment-resistant depression, a meta-analysis
of randomized, double-blind and sham-controlled study, BMC Psychiatry 14
(2014) 342, http://dx.doi.org/10.1186/s12888-014-0342-4.
[12] O' Reardon, et al., Efﬁcacy and safety of transcranial magnetic stimulation in
acute treatment of major depression: a multisite randomized controlled triall,
Biol. Psychiatry. 62 (2007) 1208e1216.
[13] K. Garcia, P. Flynn, K. Pierce, M. Caudle, Repetitive transcranial magnetic
stimulation treats postpartum depression, Brian Stimul. 3 (2010) 36e41,
http://dx.doi.org/10.1016/j.brs.2009.06.001.
[14] Myczkowski, et al., Effects of repetitive transcranial magnetic stimulation on
clinical, social, and cognitive performance in postpartum depression, Dove-
press Neuropsychiatric Dis. Treat. 8 (2012) 491e500.
[15] S. Rossi, M. Hallett, P.M. Rossini, A. Pascual-Leone, Safety, ethical consider-
ations, and application guidelines for the use of transcranial magnetic stim-
ulation in clinical practice and research, Clin. Neurophysiol. 120 (12) (2009)
2008e2039.
[16] D. Spronk, M. Arns, P.B. Fitzgerald, Repetitive Transcranial Magnetic Stimu-
lation in Depression: Protocols, Mechanisms and New Developments. Neu-
romodulation and Neurofeedback: Techniques and Applications, Elsevier,
2010.
[17] Guidance for Industry and FDA Staff Class II Special Controls Guidance
Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems, July
2011. http://www.fda.gov/RegulatoryInformation/Guidances/ucm265269.
htm.
[18] T. Pearlstein, Perinatal depression: treatment options and dilemmas,
J. Psychiatry Neurosci. 33 (4) (2008) 304.
[19] T. Pearlstein, Perinatal depression: treatment options and dilemmas,
J. Psychiatry Neurosci. 33 (4) (2008) 304.
[20] M. Huang, B. Luo, J. Hu, et al., Repetitive transcranial magnetic stimulation in
combination with citalopram in young patients with ﬁrst-episode major
depressive disorder: a double-blind, randomized, sham-controlled trial, Aust.
N. Z. J. Psychiatry 46 (3) (2012) 257e264.
[21] V. Sharma, C. Sommerdyk, Are antidepressants effective in the treatment of
postpartum depression? A systematic review, Prim. Care Companion CNS
Disord. 15 (6) (2013), http://dx.doi.org/10.4088/PCC.13r01529. PCC.13r01529.
[22] J. Lee, D. Blumberger, P. Fitzgerald, et al., The role of transcranial magnetic
stimulation in treatment-resistant depression: a review, Curr. Pharm. Des. 18
(36) (2012) 5846e5850.
[23] Ana Marusic, Stella Fatovic Ferencic, Adoption of the double dummy trial
design to reduce observer bias in testing treatments, J. R. Soc. Med. 106 (5)
(2013) 196e198. PMC. Web. 9 Dec. 2016.
T. Andriotti et al. / Contemporary Clinical Trials Communications 5 (2017) 86e91 91
